Core Viewpoint - The company, Jianfa Zhixin, is officially launching its IPO process on the Shenzhen Stock Exchange's ChiNext board, focusing on the medical device distribution industry and aiming to enhance its digital capabilities and service offerings in the healthcare sector [1][2]. Group 1: Company Overview - Jianfa Zhixin was established in 2010 and primarily engages in direct sales and distribution of medical devices, providing services such as SPD to hospitals [2]. - The company has developed a nationwide distribution network, serving over 3,300 medical institutions across 31 provinces in China, with a focus on high-value interventional products [2]. - Jianfa Zhixin has established long-term partnerships with over 100 well-known domestic and international medical device manufacturers, leveraging its strong channel coverage and professional operations [2]. Group 2: Financial Performance - From 2022 to 2024, Jianfa Zhixin's projected revenue is expected to grow from 11.882 billion yuan to 17.923 billion yuan, reflecting a compound annual growth rate (CAGR) of 22.81% [3]. - The company's main revenue source is its direct sales business, which is projected to increase from 7.797 billion yuan in 2022 to 11.032 billion yuan in 2024 [3]. - The revenue growth is attributed to the rapid increase in authorized brands and product lines, as well as the integrated development of direct and distribution businesses [3]. Group 3: Investment and Technology - Jianfa Zhixin plans to use the funds raised from the IPO to invest in digitalization and centralized management of medical consumables, enhancing its management capabilities [1][5]. - The company has developed various proprietary software systems to improve its information management and operational efficiency, holding 45 software copyrights as of the date of the prospectus [5]. - The planned allocation of raised funds includes 140 million yuan for information system upgrades, 104 million yuan for centralized operation services, and 240 million yuan for working capital [5]. Group 4: Future Outlook - Jianfa Zhixin aims to become a leading medical device distribution service provider in China by enhancing its service attributes and expanding its product diversification and integration along the supply chain [1][3]. - The company is focused on scaling its operations while ensuring compliance and information-driven management in the evolving healthcare landscape [3].

上海建发致新医疗科技集团股份有限公司 （2）公司具有较为完备的信息化基础和丰富的信息化建设经验 公司作为医疗器械流通服务商，自成立以来一直注重信息化建设的投入，不 断完善信息化管理体系，并专门设立研发中心与运维中心，包含研发团队、测试 团队、产品团队、运维团队与实施团队等，自主开发致新医疗供应链操作云平台、 智信链智慧医用耗材管理软件、致锐云供应商 SAAS 系统、WMS 致新医用耗材 第三方物流软件系统与记录产品基础信息的产品云平台软件，积累了丰富的信息 化建设经验，能够为此次信息化建设提供有力保障。 （3）公司具有信息化水平的人才基础 经公司 2022 年第二届董事会第十四次会议以及 2022 年第二次临时股东大会 审议通过，公司拟向社会公众公开发行人民币普通股（A 股）不超过 63,193,277 股，实际募集资金扣除发行费用后的净额将全部用于公司主营业务相关的项目和 营运资金，具体投资方向与使用安排如下： | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | | 序 | | 项目 | 本次募集 | 环评批复 | | | | 项目名称 | | ...